来自津巴布韦的初治且有治疗史患者中出现的整合酶未治情况下的多替拉韦耐药性。
Emergent dolutegravir resistance in integrase-naïve, treatment experienced patients from Zimbabwe.
作者信息
Mandikiyana Chirimuta Linda A, Pascoe Margaret J, Lowe Sara
机构信息
Newlands Clinic, Ruedi Luethy Foundation, Harare, Zimbabwe.
出版信息
South Afr J HIV Med. 2022 Oct 26;23(1):1435. doi: 10.4102/sajhivmed.v23i1.1435. eCollection 2022.
Abstract
UNLABELLED
We report two cases of dolutegravir (DTG) resistance in highly treatment experienced patients. Monitoring for treatment failure and adherence support is important in highly treatment experienced patients taking DTG.
WHAT THIS STUDY ADDS
Dolutegravir is the mainstay of HIV treatment programmes and emergence of drug resistance to DTG is of public health relevance.
摘要
未标注
我们报告了两例在接受过高度治疗的患者中出现多替拉韦（DTG）耐药的病例。对于服用DTG的高度治疗经验患者，监测治疗失败情况和提供依从性支持很重要。
本研究的新增内容
多替拉韦是HIV治疗方案的主要药物，对DTG出现耐药性具有公共卫生意义。
相似文献
1
Emergent dolutegravir resistance in integrase-naïve, treatment experienced patients from Zimbabwe.
South Afr J HIV Med. 2022 Oct 26;23(1):1435. doi: 10.4102/sajhivmed.v23i1.1435. eCollection 2022.
2
Emergent Resistance to Dolutegravir Among INSTI-Naïve Patients on First-line or Second-line Antiretroviral Therapy: A Review of Published Cases.
Open Forum Infect Dis. 2020 Jun 2;7(6):ofaa202. doi: 10.1093/ofid/ofaa202. eCollection 2020 Jun.
3
Case report: Emergence of dolutegravir resistance in a patient on second-line antiretroviral therapy.
South Afr J HIV Med. 2020 Jul 2;21(1):1062. doi: 10.4102/sajhivmed.v21i1.1062. eCollection 2020.
4
Short Communication: Dolutegravir-Based Regimens Are Active in Integrase Strand Transfer Inhibitor-Naive Patients with Nucleoside Reverse Transcriptase Inhibitor Resistance.
AIDS Res Hum Retroviruses. 2018 Apr;34(4):343-346. doi: 10.1089/AID.2017.0184. Epub 2018 Mar 22.
5
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.
Lancet. 2013 Aug 24;382(9893):700-8. doi: 10.1016/S0140-6736(13)61221-0. Epub 2013 Jul 3.
6
The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 Integration.
mBio. 2017 Apr 4;8(2):e00157-17. doi: 10.1128/mBio.00157-17.
7
The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance.
J Virol. 2015 Nov;89(22):11269-74. doi: 10.1128/JVI.01881-15. Epub 2015 Aug 26.
8
The M184I/V and K65R nucleoside resistance mutations in HIV-1 prevent the emergence of resistance mutations against dolutegravir.
AIDS. 2016 Sep 24;30(15):2267-73. doi: 10.1097/QAD.0000000000001191.
9
Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 Study.
Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0164521. doi: 10.1128/AAC.01645-21. Epub 2021 Oct 25.
10
Differential effects of the G118R, H51Y, and E138K resistance substitutions in different subtypes of HIV integrase.
J Virol. 2015 Mar;89(6):3163-75. doi: 10.1128/JVI.03353-14. Epub 2014 Dec 31.
引用本文的文献
1
Drug-drug interaction between dolutegravir and artemether-lumefantrine in HIV and malaria mono- and co-infections: a pharmacogenetic analysis from Ghana.
AIDS Res Ther. 2025 Aug 30;22(1):85. doi: 10.1186/s12981-025-00787-9.
2
Development and Optimization of Oligonucleotide Ligation Assay (OLA) Probes for Detection of HIV-1 Resistance to Dolutegravir.
Viruses. 2024 Jul 19;16(7):1162. doi: 10.3390/v16071162.
3
Virologic outcomes on dolutegravir-, atazanavir-, or efavirenz-based ART in urban Zimbabwe: A longitudinal study.
PLoS One. 2024 Feb 23;19(2):e0293162. doi: 10.1371/journal.pone.0293162. eCollection 2024.
4
Outcomes and characteristics of patients on protease inhibitors at a tertiary level antiretroviral clinic.
South Afr J HIV Med. 2023 Dec 21;24(1):1536. doi: 10.4102/sajhivmed.v24i1.1536. eCollection 2023.
5
Treatment Emergent Dolutegravir Resistance Mutations in Individuals Naïve to HIV-1 Integrase Inhibitors: A Rapid Scoping Review.
Viruses. 2023 Sep 15;15(9):1932. doi: 10.3390/v15091932.
本文引用的文献
1
Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial.
Lancet HIV. 2022 Jun;9(6):e381-e393. doi: 10.1016/S2352-3018(22)00092-3. Epub 2022 Apr 20.
2
Transmitted drug resistance to NRTIs and risk of virological failure in naïve patients treated with integrase inhibitors.
HIV Med. 2021 Jan;22(1):22-27. doi: 10.1111/hiv.12956. Epub 2020 Sep 23.
3
Emergent Resistance to Dolutegravir Among INSTI-Naïve Patients on First-line or Second-line Antiretroviral Therapy: A Review of Published Cases.
Open Forum Infect Dis. 2020 Jun 2;7(6):ofaa202. doi: 10.1093/ofid/ofaa202. eCollection 2020 Jun.
4
Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial.
Lancet Infect Dis. 2019 Mar;19(3):253-264. doi: 10.1016/S1473-3099(19)30036-2. Epub 2019 Feb 4.
Zotero 插件